½ÃÀ庸°í¼­
»óǰÄÚµå
1363531

¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ä¡·á À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° µ¿Çâ(2023-2030³â)

Urolithiasis Management Devices Market Size, Share & Trends Analysis Report By Treatment Type (Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy), By End-use, By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 115 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

¼¼°èÀÇ ¿ä·Î°á¼® °ü¸® ±â±â(Urolithiasis Management Devices) ½ÃÀåÀº 2030³â±îÁö 22¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

2023³âºÎÅÍ 2030³â±îÁöÀÇ CAGRÀº 4.9%·Î ÃßÀÌÇϸç È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù. ¼ö³â¿¡ °ÉÃÄ ¿ä·Î °á¼®ÀÇ ÀÌȯÀ²ÀÇ ¿ì·ÁÀûÀÎ Áõ°¡´Â Ä¡·á ¿É¼ÇÀÇ Áøº¸ÀÇ ¿øÀÎÀÌ µÇ¾ú½À´Ï´Ù. À¯·´ºñ´¢±â°úÇÐȸ¿¡ µû¸£¸é, ¿ä·Î°á¼®ÁõÀº À¯º´·ü 10%ÀÇ °¡Àå ÈçÇÑ »ýȰ½À°üº´ Áß ÇϳªÀ̸ç ü°èÀûÀÎ Ä¡·á¹æ¹ýÀÌ ÇÊ¿äÇÏ´Ù°í ÇÕ´Ï´Ù.

¿ä·Î°á¼®ÁõÀº ÁÖ·Î ½ÅÀå, ¿ä°ü, ¹æ±¤À» ºñ·ÔÇÑ ºñ´¢±â°è¿¡ °á¼®ÀÌ »ý±â´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. ¿ä·Î°á¼®ÁõÀº ¹Ì±¹, ij³ª´Ù, µ¶ÀÏ µî ÇÏÀÌ ¿£µå ±¹°¡¿¡¼­ ÁÖµÈ °Ç°­ °ü¸® ¹®Á¦ÀÌ¸ç ´ëºÎºÐÀÇ °æ¿ì 50%ÀÇ Àç¹ß·üÀ» ³ªÅ¸³À´Ï´Ù. ¿ä·Î°á¼®ÁõÀº »ýȰ ½À°ü °³¼±, ½Ä´Ü °ü¸®, ±âº» ¾à¹° Ä¡·á·Î °ü¸® ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÉÇÑ ÅëÁõÀ» À¯¹ßÇÏ´Â Å« °á¼®À» Á¦°ÅÇϱâ À§Çؼ­´Â ´Ù¾çÇÑ Ä¡·á Á¢±Ù¹ýÀ» äÅÃÇØ¾ßÇÕ´Ï´Ù. °á¼®ÀÇ Å©±â, ½ÅüÀÇ À§Ä¡, ¼Òº¯ »ý½Ä°üÀÇ ÇØºÎÇÐÀû º¯È­¿¡ µû¶ó ħ½ÀÀûÀ̰ųª ºñ ħ½ÀÀûÀÎ °á¼® Á¦°Å ¹æ¹ýÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ÀÛÀº °á¼®Àº ü¿Ü Ãæ°ÝÆÄ(ü¿Ü Ãæ°ÝÆÄ °á¼® ÆÄ¼â¼ú)·Î, Å« °á¼®Àº ¼ö¼ú(ü¿Ü Ãæ°ÝÆÄ °á¼® ÆÄ¼â¼ú ¶Ç´Â °æÇÇÀû ¿ä·Î°á¼® ÀûÃâ¼ú)À¸·Î Á¦°ÅÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÛÀº °á¼®Àº ÀϹÝÀûÀ¸·Î ¿Ü°úÀû °³ÀÔÀ» ÇÊ¿ä·Î ÇÏÁö ¾ÊÀ¸¸ç ¾à¹° ¿ä¹ý°ú °Ç°­ÇѽÄÀÌ ¿ä¹ýÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª °á¼®ÀÌ Ä¿Áö¸é °á¼®À» Á¦°ÅÇϱâ À§ÇØ ´Ù¾çÇÑ Á¢±Ù¹ýÀÌ ÇÊ¿äÇÕ´Ï´Ù. ü¿Ü °á¼® ÆÄ¼â¼úÀº °á¼® Á¦°Å¸¦ À§ÇØ Ã¤ÅõǴ ÀϹÝÀûÀÎ Ä¡·á¹ý Áß ÇϳªÀ̸ç 2015³â ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÕ´Ï´Ù. ü³» °á¼® ÆÄ¼â¼úÀº ³»½Ã°æÀÇ µµ¿òÀ¸·Î °á¼®¿¡ ÀÚ¸®¸¦ Àâ°í ÀÛ°Ô ¸¸µå´Â Ä¡·á¹ýÀÔ´Ï´Ù. °á¼®ÀÇ ºØ±«¿¡´Â ÃÊÀ½ÆÄ ¶Ç´Â ·¹ÀÌÀú ±â¼úÀÌ »ç¿ëµÇ¾î ÀÛÀº Á¶°¢ÀÌ ¿ä·Î ½Ã½ºÅÛÀ» Åë°ú ÇÒ ¼ö ÀÖ½À´Ï´Ù. ü³» °á¼® ÆÄ¼â¼úÀº ¹«°á¼®È­À²ÀÌ ³ô±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È Ä¡·á ¿É¼ÇÀ¸·Î ¼±È£µË´Ï´Ù.

°Ô´Ù°¡, °æÇÇÀû ¿ä·Î°á¼® Á¦°Å¼úÀº ü¿Ü ¶Ç´Â ü³» °á¼® ÆÄ¼â¼úÀÌ È¿°ú°¡ ¾ø°í º¸Åë 1ÁÖ°£ ÀÔ¿øÀÌ ÇÊ¿äÇÑ °æ¿ì¿¡ ´õ Å« °á¼®À» Á¦°ÅÇϱâ À§ÇØ ¼öÇàµÇ´Â ¼ö¼úÀû Á¢±Ù¹ýÀÔ´Ï´Ù.

¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)´Â ½Ã°£ ¹× ºñ¿ë Àý°¨ ÇýÅÃÀ¸·Î ÀÎÇØ ÀüÅëÀûÀÎ º´¿ø ¹× Ŭ¸®´Ð ȯ°æ¿¡ ºñÇØ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·ÎÀÌ ÃÖÁ¾ ¿ëµµ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ¼öÀͼºÀÖ´Â ¼ºÀå·üÀ» ±â·Ï ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ªÀº ½Ã°£¿¡ ºñ´¢±â °èÅë¿¡¼­ °á¼®À» È¿°úÀûÀ¸·Î Á¦°ÅÇϱâ À§ÇØ ³»½Ã°æ ¹× °¡ÀÌµå ¿ÍÀ̾î, ¸Þ½º ¹× ¹Ù½ºÄÏÀ» Æ÷ÇÔÇÑ ¸¶ÀÌÅ©·Î ¾×¼¼¼­¸®¿Í °°Àº »õ·Î¿î ¼ö¼ú ±â¼úÀÇ µµÀÔÀ¸·Î ÃÖ¼Ò Ä§½À ¼ö¼úÀÇ Àü¹ÝÀûÀÎ ¼ö¿ë¼ºÀÌ Çâ»óµÇ¾ú½À´Ï´Ù.

¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå º¸°í¼­ÀÇ ÇÏÀ̶óÀÌÆ®

  • ¿ä·Î°á¼®Àº ¼¼°èÀûÀ¸·Î ¸Å¿ì ¸¸¿¬Çϰí ÀÖÀ¸¸ç, ¼¼°èÀÇ ´ë»óÀα¸´Â 15%, Àç¹ß·üÀº 50%ÀÔ´Ï´Ù. ³²¼ºÀº ¿©¼ºº¸´Ù ¿ä·Î°á¼®ÀÌ µÇ±â ½±½À´Ï´Ù.
  • ü³» °á¼® ÆÄ¼â¼ú ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí, 2022³â¿¡´Â 34.6%ÀÇ ÃÖ´ë ¼öÀÍ Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ¿¹Ãø ±â°£¿¡´Â 6.8%ÀÇ °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ü³» °á¼® ÆÄ¼â¼úÀº ³»½Ã°æÀ» »ç¿ëÇÏ¿© °á¼®À» ½Ã°¢È­ÇÏ°í ·¹ÀÌÀú¸¦ »ç¿ëÇÏ¿© °ü¸® °¡´ÉÇÑ Á¶°¢À¸·Î µ¿½Ã¿¡ ºÐÇØÇÕ´Ï´Ù.
  • ¼±Áø±¹¿¡¼­ °Ç°­¿¡ ÇØ·Î¿î ½Äǰ ¼Òºñ Áõ°¡¿Í ÇÔ²², ÁÂ½Ä »ýȰ ¹æ½ÄÀÇ Ã¤ÅÃÀÌ Áõ°¡ °æÇâÀÌ ÀÖ´Â °ÍÀÌ ¿ä·Î°á¼®ÀÇ ¹ß»ý·ü »ó½ÂÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¿Ü·¡ ¼ö¼ú ¼­ºñ½º Á¦°ø¾÷ü´Â ƯÈ÷ ¼±Áø±¹¿¡¼­ °Ç°­¿¡ ÇØ·Î¿î ¶óÀÌÇÁ ½ºÅ¸ÀÏ º¯È­ÀÇ °á°ú·Î Ä¡·á ¼ö¿äÀÇ ±ÞÁõÀ» °æÇèÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼öÀûÀÎ ½ÃÀå Àü¸Á
  • º¸±Þ ¹× ¼ºÀå Àü¸Á ¸ÅÇÎ
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ ºÐ¼®
  • ¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå ºÐ¼® Åø
    • »ê¾÷ ºÐ¼®-Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ¿ä·Î°á¼® °ü¸® ±â±â : Ä¡·á À¯Çüº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå : µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â, 2030³â)
  • ü¿Ü Ãæ°ÝÆÄ °á¼® ÆÄ¼â¼ú(ESWL)
    • ü¿Ü Ãæ°ÝÆÄ °á¼® ÆÄ¼â¼ú
  • ü³» °á¼® ÆÄ¼â¼ú
    • ü³» °á¼® ÆÄ¼â¼ú ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
  • °æÇÇÀû ¿ä·Î°á¼® Àý°³¼ú
    • °æÇÇÀû ¿ä·Î°á¼® Àý°³¼ú ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
  • ±âŸ Ä¡·á¹ý
    • ±âŸ Ä¡·á¹ý ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)

Á¦5Àå ¿ä·Î°á¼® °ü¸® ±â±â : ÃÖÁ¾ »ç¿ëº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå : µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â, 2030³â)
  • º´¿ø ¹× Ŭ¸®´Ð
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)

Á¦6Àå ¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° Àü¸Á
  • Áö¿ªº° ¿ä·Î°á¼® °ü¸® ±â±â ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ºÏ¹Ì
    • ºÏ¹Ì ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
  • ¾Æ½Ã¾Æ ÅÂÆò¾ç
    • ¾Æ½Ã¾Æ ÅÂÆò¾ç ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ³²¹Ì
    • ³²¹Ì ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • MEA ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦7Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ ¹× ¿µÇ⠺м®
  • ½ÃÀå ÁøÃâ±â¾÷ ºÐ·ù
    • Allengers
    • Boston Scientific
    • BD
    • Cook Medical
    • ConMed
    • DirexGroup
    • Dornier MedTech
    • Potent Optotronic
    • HealthTronics
    • Karl Storz
    • Lumenis
    • Olympus
    • Richard Wolf
    • Siemens Healthcare
LYJ 23.10.30

Urolithiasis Management Devices Market Growth & Trends:

The global urolithiasis management devices market was valued at USD 2.21 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 4.9% from 2023 to 2030. The alarming growth in the incidence rate of urinary stones, over the years, is responsible for the advancements in the treatment options. European Association of Urology states that it is one of the most common lifestyle disorders with a 10% prevalence rate and requires a systematic treatment approach.

Urolithiasis means formation of stones in the urinary system, mainly including the kidney, ureters, and the bladder. It is a major healthcare concern in the high end countries such as the U.S., Canada, and Germany with a recurrence rate of 50% in most of the cases. Urolithiasis can be managed with the help of lifestyle changes, controlled diet, or basic medication. However, various treatment approaches need to be adopted for the removal of large stones that cause severe pain. Depending upon the stone size, location in the body, and anatomical variations in the urogenital tract, invasive or noninvasive stone removal procedures are available. For instance, smaller stones can be tackled with external shock waves (extracorporeal shock wave lithotripsy), while larger stones can be removed through surgeries (intracorporeal lithotripsy or percutaneous nephrolithotomy).

Smaller stones generally do not require surgical interventions and can be cured with the help of medication and a healthy diet. However, larger stones necessitate different approaches for their elimination. Extracorporeal lithotripsy is one of the common treatments employed for stone elimination and held a majority market share in the year 2015. Intracorporeal lithotripsy treatments spot and reduce the stones to smaller pieces with the help of endoscopy. For the disintegration of stones, ultrasound or laser techniques are used to enable the passage of smaller fragments through the urinary system. Owing to the effective stone-free rate offered by intracorporeal lithotripsy, it is likely to be preferred as a treatment option during the forecast period.

Furthermore, percutaneous nephrolithotomy is a surgical approach deployed to eliminate larger stones where extracorporeal or intracorporeal lithotripsies prove to be ineffective and typically require a week's hospitalization.

Ambulatory surgical centers are gaining popularity over traditional hospital and clinic settings due to the time and cost saving benefits. As a result, this end-use segment is expected to record a lucrative growth rate during the forecast period. Introduction of novel surgical technologies, such as endoscopy and micro accessories including guidewires, scalpels, and baskets, to effectively expel stones from the urinary system in a short time has enhanced the overall acceptability of minimally invasive surgeries.

Urolithiasis Management Devices Market Report Highlights:

  • Urinary stones are highly prevalent worldwide with a 15% global target population and the recurrence rate of 50%. Men are more susceptible to developing renal stones than women.
  • The intracorporeal lithotripsy segment dominated the market and held the largest revenue share of 34.6% in 2022 and is expected to grow at the fastest CAGR of 6.8% over the forecast period. Intracorporeal lithotripsy involves the visualization of stones using an endoscope and their simultaneous disintegration into manageable fragments using lasers.
  • The upward trend in the adoption of sedentary lifestyle coupled with increased consumption of unhealthy food in the developed countries is responsible for the rising incidence of kidney stones. Ambulatory surgical service providers are expected to experience a surge in the treatment demand as a result of the unhealthy lifestyle changes, especially in the developed countries.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment type
    • 1.1.2. End use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Urolithiasis Management Devices Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Urolithiasis Management Devices Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Urolithiasis Management Devices: Treatment Type Estimates & Trend Analysis

  • 4.1. Urolithiasis Management Devices Market: Key Takeaways
  • 4.2. Urolithiasis Management Devices Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Extracorporeal Shock Wave Lithotripsy (ESWL)
    • 4.3.1. Extracorporeal shock wave lithotripsy (ESWL) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Intracorporeal Lithotripsy
    • 4.4.1. Intracorporeal lithotripsy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Percutaneous Nephrolithotomy
    • 4.5.1. Percutaneous nephrolithotomy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Other Treatments
    • 4.6.1. Other treatments market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Urolithiasis Management Devices: End Use Estimates & Trend Analysis

  • 5.1. Urolithiasis Management Devices Market: Key Takeaways
  • 5.2. Urolithiasis Management Devices Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals & Clinics
    • 5.3.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Ambulatory Surgical Centers (ASCs)
    • 5.4.1. Ambulatory surgical centers (ASCs) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Urolithiasis Management Devices Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Urolithiasis Management Devices Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. North America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. U.S. market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Canada market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. Europe market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. UK
      • 6.4.2.1. UK market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Germany market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. France
      • 6.4.4.1. France market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Italy market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Spain market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Sweden market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Norway
      • 6.4.8.1. Norway market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.9. Denmark
      • 6.4.9.1. Denmark market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Japan market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. China
      • 6.5.3.1. China market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. India
      • 6.5.4.1. India market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Australia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Thailand market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.7. South Korea
      • 6.5.7.1. South Korea market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Brazil market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Mexico
      • 6.6.3.1. Mexico market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.4. Argentina
      • 6.6.4.1. Argentina market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. MEA market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Saudi Arabia market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. South Africa
      • 6.7.3.1. South Africa market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. UAE market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Kuwait market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Allengers
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Boston Scientific
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. BD
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Cook Medical
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. ConMed
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. DirexGroup
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Dornier MedTech
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Potent Optotronic
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. HealthTronics
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Karl Storz
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Lumenis
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Olympus
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. Richard Wolf
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Siemens Healthcare
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦